Olutasidenib to prevent cancer return after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests if a daily pill called olutasidenib can help keep your cancer from coming back after a stem cell transplant. It's for people with a specific IDH1 gene change and myeloid cancers like AML or MDS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a myeloid cancer (like AML, MDS, MPN, or CMML) and had a stem cell transplant 30 to 120 days ago.
- Your original cancer had a change in the IDH1 gene.
- Your blood counts are recovering well after transplant, without needing daily growth factor shots or platelet transfusions.
- You are in remission (bone marrow blasts less than 5%) and are between 18 and 75 years old.
- You are generally active (ECOG 0, 1, or 2) and your kidneys and liver are working well enough.
- You do not have uncontrolled infections, significant graft-versus-host disease, or other serious health problems that would make the study unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
This trial tests a drug called olutasidenib for people with certain blood cancers (AML, MDS, or CMML) that have a specific IDH1 gene change. The goal is to see if it can help prevent relapse after a donor stem cell transplant.
This trial tests a drug called olutasidenib, either alone or with other treatments, to see if it can help keep your AML in remission after you've finished your first round of therapy. It's for people whose AML has a specific change in the IDH1 gene.
This trial tests an oral drug called olutasidenib in people with certain low-risk blood cancers or a pre-cancer condition. It may help by targeting a specific genetic change (IDH1 mutation) found in your blood cells.
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
This trial tests a targeted drug, olutasidenib, for people with AML or MDS whose cancer cells have an IDH1-R132 mutation. Depending on your specific diagnosis, you may receive olutasidenib alone or combined with other medicines.
Hear when a new Myeloid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.